F-star Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
Rhea-AI Summary
F-star Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the 32nd Annual Oppenheimer Healthcare Conference, scheduled for March 15-17, 2022. The company's CEO, Eliot Forster, will present on March 17, 2022, from 12:40 PM to 1:10 PM ET. F-star is focusing on advancing next-generation immunotherapies, particularly utilizing bispecific antibodies for cancer treatment. The company boasts over 500 patents and is actively engaged in partnerships addressing unmet needs across oncology and other areas.
Positive
- None.
Negative
- None.
News Market Reaction – FSTX
In the trading session that priced this news, FSTX gained 1.01%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that management will be presenting a corporate overview and be available for 1-on-1 meetings at the 32nd Annual Oppenheimer Healthcare Conference taking place virtually on March 15-17, 2022.
32nd Annual Oppenheimer Healthcare Conference (virtual)
Date: March 17th, 2022
Presentation Time: 12:40pm – 1:10pm ET
Speaker: Eliot Forster, Chief Executive Officer
Format: Company Presentation
A replay will be available following the presentation for 90 days
About F-star Therapeutics, Inc.
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer. F-star is pioneering the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in cancer therapy. The Company has four second-generation immuno-oncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate. F-star has over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several disease areas, including oncology, immunology, and CNS.
For more information visit our website and follow us on LinkedIn and Twitter.
For further information, please contact:
For investor inquiries:
Lindsey Trickett
VP Investor Relations & Communications
+1 240 543 7970
lindsey.trickett@fstar.com
John Fraunces
Managing Director
LifeSci Advisors LLC
+1 917 355 2395
jfraunces@lifesciadvisors.com
For media inquiries:
Helen Shik
Shik Communications LLC
+1 617-510-4373
helen@shikcommunications.com
